A detailed history of Susquehanna International Group, LLP transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 10,202 shares of RAPT stock, worth $11,324. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,202
Previous 11,134 8.37%
Holding current value
$11,324
Previous $33,000 39.39%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.76 - $3.75 $1,640 - $3,495
-932 Reduced 8.37%
10,202 $20,000
Q2 2024

Aug 15, 2024

SELL
$2.89 - $9.38 $146,927 - $476,879
-50,840 Reduced 82.03%
11,134 $33,000
Q1 2024

May 07, 2024

BUY
$6.87 - $26.45 $303,949 - $1.17 Million
44,243 Added 249.52%
61,974 $556,000
Q4 2023

Feb 14, 2024

BUY
$11.28 - $25.46 $200,005 - $451,431
17,731 New
17,731 $440,000
Q1 2023

May 16, 2023

BUY
$17.19 - $30.8 $591,095 - $1.06 Million
34,386 Added 229.55%
49,366 $905,000
Q4 2022

Feb 14, 2023

SELL
$16.28 - $24.6 $209,442 - $316,479
-12,865 Reduced 46.2%
14,980 $296,000
Q3 2022

Nov 14, 2022

BUY
$17.96 - $30.46 $500,096 - $848,158
27,845 New
27,845 $670,000
Q1 2022

May 16, 2022

SELL
$17.02 - $40.22 $208,512 - $492,735
-12,251 Reduced 31.53%
26,608 $585,000
Q4 2021

Feb 14, 2022

BUY
$29.5 - $39.5 $881,047 - $1.18 Million
29,866 Added 332.1%
38,859 $1.43 Million
Q2 2021

Aug 11, 2021

SELL
$17.99 - $40.02 $225,072 - $500,690
-12,511 Reduced 58.18%
8,993 $286,000
Q1 2021

May 17, 2021

BUY
$16.0 - $24.46 $344,064 - $525,987
21,504 New
21,504 $477,000

Others Institutions Holding RAPT

About RAPT Therapeutics, Inc.


  • Ticker RAPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,656,600
  • Market Cap $32.9M
  • Description
  • RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...
More about RAPT
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.